General
Preferred name
AMIODARONE
Synonyms
AMIODARONE HYDROCHLORIDE ()
Amiodarone HCl ()
Nexterone ()
Amiodar ()
Amiodarone (HCl) ()
Amiodarone (hydrochloride) ()
Amiodarone (NSC 85442) HCl ()
Amiodar,Amiodarone hydrochloride,Nexterone ()
Cordarone X ()
Trangorex ()
Cordarone X 100 ()
NSC-85442 ()
Amiodarone ()
SKF-33134-A ()
Cordarone X 200 ()
VF-236 ()
Ortacrone ()
SK&F-33134-A ()
Ritmocardyl ()
Cordarone ()
L-3428 ()
Miodaron ()
Darmil ()
Pacerone ()
Amidox ()
Amyben ()
NSC-343341 ()
SKF 33134-A ()
Amiodarone-d4 (hydrochloride) ()
P&D ID
PD009796
CAS
19774-82-4
1951-25-3
1216715-80-8
Tags
obsolete probe
nuisance
natural product
drug
available
Approved by
FDA
First approval
1985
Drug Status
investigational
approved
Drug indication
Coronavirus Disease 2019 (COVID-19)
Tachyarrhythmias
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
METABOLISM Amiodarone is extensively metabolized in the liver via CYP2C8 (under 1% unchanged in urine), and can effect the metabolism of numerous other drugs. The major metabolite of amiodarone, desethylamiodarone (DEA), also exhibits antiarrhythmic properties.
DESCRIPTION Amiodarone is a class III antiarrhythmic drug and acts as a positive inotropic agent. The prescription drug contains amiodarone hydrochloride (PubChem CID 441325). (GtoPdb)
PHARMACODYNAMICS Amiodarone belongs to a class of drugs called Vaughan-Williams Class III antiarrhythmic agents. It is used in the treatment of a wide range of cardiac tachyarhthmias, including both ventricular and supraventricular (atrial) arrhythmias. After intravenous administration in man, amiodarone relaxes vascular smooth muscle, reduces peripheral vascular resistance (afterload), and slightly increases cardiac index. Amiodarone prolongs phase 3 of the cardiac action potential. It also mediates effects that are similar to those of antiarrhythmic classes Ia, II, and IV. Amiodarone shows beta blocker-like and calcium channel blocker-like actions on the SA and AV nodes, increases the refractory period via sodium- and potassium-channel effects, and slows intra-cardiac conduction of the cardiac action potential, via sodium-channel effects.
DESCRIPTION alpha and beta adrenoceptor agonist; inhibits binding of 1,4-dihydropyridine to L-type Ca2+ channels; coronary vasodilator (LOPAC library)
DESCRIPTION Amiodarone HCl is a sodium/potassium-ATPase inhibitor and an autophagy activator, used to treat various types of cardiac dysrhythmias. (BOC Sciences Bioactive Compounds)
DESCRIPTION Inhibitor of neuronal NaV channels; anticonvulsant (Tocris Bioactive Compound Library)
Cell lines
5
Organisms
2
Compound Sets
35
AdooQ Bioactive Compound Library
A11798
BOC Sciences Bioactive Compounds
amiodarone-hcl-cas-19774-82-4-item-84-62197
Cayman Chemical Bioactives
15213
10010668
ChEMBL Approved Drugs
CHEMBL1083993
CHEMBL633
ChEMBL Drugs
CHEMBL1083993
CHEMBL633
Concise Guide to Pharmacology 2017/18
2566
Concise Guide to Pharmacology 2019/20
2566
Concise Guide to Pharmacology 2021/22
2566
Concise Guide to Pharmacology 2023/24
2566
Drug Repurposing Hub
DrugBank
DB01118
DrugBank Approved Drugs
DB01118
DrugCentral
176
DrugCentral Approved Drugs
176
DrugMAP
DMN6F1W
DMUTEX3
DrugMAP Approved Drugs
DMUTEX3
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
2566
Ki Database
Amiodarone
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL633
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
CHEMBL633
MedChem Express Bioactive Compound Library
HY-14188
NCATS Inxight Approved Drugs
N3RQ532IUT
NIH Clinical Collections (NCC)
NPC Screening Collection
Nuisance compounds in cellular assays
Obsolete Compounds
amiodarone
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
amiodarone-hcl
TargetMol Bioactive Compound Library
T1496
The Spectrum Collection
Tocris Bioactive Compound Library
4095
External IDs
75
Properties
(calculated by RDKit )
Molecular Weight
645.02
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
0
Rotatable Bonds
11
Ring Count
3
Aromatic Ring Count
3
cLogP
6.94
TPSA
42.68
Fraction CSP3
0.4
Chiral centers
0.0
Largest ring
6.0
QED
0.17
Structural alerts
4
aggregator (Aggregator Advisor)
Aggregators
aggregator (ZINC)
Aggregators
CAD
Nuisance compounds in cellular assays
historic compounds (Chemical Probes.org)
Obsolete
Related compounds
Custom attributes
(extracted from source data)
Selectivity
alpha/beta
Target
Autophagy
Potassium Channel
??-adrenergic receptor
ATP-sensitive potassium channel
ADRB1, CACNA1H, CACNA2D2, KCNA7, KCNH2
Autophagy,Potassium Channel
Pathway
Membrane Transporter/Ion Channel
GPCR/G protein
Primary Target
Other Channel Modulators
Indication
ventricular arrhythmias
MOA
potassium channel blocker
Therapeutic Class
Antiarrhythmic Agents
Antiviral Agents
Source data